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http://dx.doi.org/10.1016/j.jmu.2013Radiofrequency ablation (RFA) is one of the curative treatment modalities for small (diameter,
3cm)orearly stage(single tumor5cmindiameterorupto three tumorsof3cmdiametereach)
hepatocellular carcinoma (HCC). RFA is more commonly used than other local ablative modalities
because the technique is highly effective, minimally invasive, and requires fewer sessions. RFA is
advocated as the first-line curative therapy for unresectable or even resectable very early stage
or early stage HCC based on a survival rate comparable to that seen with resection. Although RFA
is highly effective for local ablation of small HCC tumors, current RFA procedures are less effective
against tumors that are in high-risk or difficult-to-ablate locations, are poorly visualized on ultraso-
nography (US), are associatedwithmajor complications, and are large (>3 cm in diameter). Recent
advances can overcome these issues by creation of artificial ascites or pleural effusion, application
of real-timevirtual US assistance, incorporationof contrast-enhancedUSbefore or after RFA, use of
combination therapy before RFA, or switching RF controller with multiple electrodes. This review
article provides updates on the clinical outcomes and advances in RFA in the treatment of HCC, par-
ticularly the aforementioned issues.
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10 S.-M. LinIntroduction
Hepatocellular carcinoma (HCC) is the fourth most common
cancer worldwide [1]. Current diagnostic modalities and
surveillance programs can detect HCC at early stages [2],
and various curative modalities [including surgical resec-
tion, orthotopic liver transplantation (OLT), and local
ablation] can achieve 5-year overall survival rates of
50e70% [3e6]. Because of underlying loss of liver function
and shortage of donor livers, resection and OLT are un-
commonly used as a first-line therapy for small HCC tumors
(diameter, 3 cm) [3e6]. Therefore, local ablative
therapies [including percutaneous ethanol injection (PEI),
percutaneous acetic acid injection, radiofrequency abla-
tion (RFA), and microwave ablation (MWA)] have been
suggested for the treatment of small HCC tumors [3e7].
Since the introduction of RFA for liver cancer in 1993,
numerous groups have reported the use of RFA. The tech-
nique has gained more attention than other local ablative
modalities for the treatment of HCC because of more pre-
dictable ablation extent, high effectiveness, minimal
invasiveness, and the need for fewer treatment sessions
[8e12]. RFA also provides survival rates equivalent to those
seen with surgical resection for small HCC tumors [13e17].
As a result, RFA has been advocated as a first-line curative
therapy for very early stage [i.e., Barcelona Clinical Liver
Cancer (BCLC) Stage 0] [4] or unresectable early stage
(BCLC Stage A) HCC [13e17]. Although RFA is highly effec-
tive for treating small HCC tumors, application of the
technique is potentially limited for tumors in high-risk or
difficult-to-ablate locations, for tumors that are poorly
visualized under ultrasonography (US), for HCC with major
complications, and for large tumors (diameter, >3 cm)
[13e19]. Recent advances can overcome these issues by
artificial instillation of intraperitoneal or intrapleural fluid
before RFA [20,21], application of contrast-enhanced US
before or after RFA [22,23], real-time virtual sonography
assistance [24,25], combination therapy before RFA, or
switching radiofrequency (RF) controller with multiple
electrodes [26e28]. This review article provides updates on
the clinical outcomes and advances in RFA therapies, par-
ticularly in the context of the aforementioned issues.
Current role of RFA in HCC
Based on the results from several randomized controlled
trials and meta-analyses, RFA has been accepted in various
HCC guidelines as a first-line curative therapy for small HCC
tumors [3e6,29e32]. The high reproducibility of RFA also
makes the technique particularly appealing for treatment
of intrahepatic recurrences after the application RFA or
other ablative therapies [33,34].
Because of extreme shortages of donor livers for OLT, RFA,
and transarterial chemoembolization are currently accepted
asbridge therapies for early stageHCCpatients awaiting liver
transplantation [35e37]. It has been shown that tumor pro-
gression beyond 12 months increased markedly after RFA for
early stage HCC, particularly for patients in whom initial
complete ablation failed and who exhibited baseline a-
fetoprotein (AFP) above 200 ng/mL and ChildePugh B status
[38]. Therefore, prompt transplantation is required forpatients with risk factors in early stage HCC after RFA. We
also found that a delay (>5 weeks after diagnosis) in RFA
treatment of early stage HCC may impact the survival of
patients with HCC detected in a surveillance program [39].Complete ablation of HCC after RFA
A conventional RFAdevicewith a single electrodeor deployed
electrode and 3e4 cm thermal diameter placed into the
tumor provided a complete ablation rate of over 90% for small
tumors (diameter,3 cm), but yielded lower rates of 53e61%
for medium-sized tumors (diameter, 3.1e5 cm) and 20e45%
for larger tumors (>5 cm) [40e43]. Therefore, various novel
devices, including a switching RF controller with two to six
unipolar or bipolar electrodes, have been proposed with the
aim of providing a larger ablation zone in a shorter time,
reducing the number of overlapping ablations required, and
creating a larger safety margin for HCC measuring >3 cm. A
few preliminary results are available; notably, Lee et al
reported that this device showed a 97% rate of complete
ablation in HCC of 3.1e5 cm in diameter [26e28]. A deployed
RF electrode was reported to provide a 5e7 cm diameter
ablation with a single electrode placement, but the shape of
thedomain ablatedby such anelectrodewasnot circular, and
the device’s multiple tines had the potential to puncture
adjacent vital structures [44]; therefore, the use of this de-
vice is not common.
Some refined algorithms can also enhance complete
ablation or simplify the application of RFA. In our experi-
ence, an interactive algorithm was more effective than the
standard algorithm when using a LeVeen deployed elec-
trode, particularly for HCC larger than 2 cm in diameter
[45]. We also found that combined use of PEI and RFA
achieved comparable levels of complete ablation for tu-
mors that were adjacent to a larger vessel (>3 mm in
diameter, i.e., vessels expected to induce a heat-sink ef-
fect) and for tumors located close to vital structures [46].
In addition, the inhibition of angiogenesis (by transarterial
chemoembolization or medication with thermo-
doxorubicin) prior to RFA has been reported (or proposed)
to enhance the degree of complete ablation [47e51].Local tumor progression (i.e., local
recurrence) of HCC after RFA
In contrast to the efficacy seen with resection, local recur-
rence (LR) rates of small HCCs after RFA were 1.3e14% at 1
year, 1.7e24% at 2 years, and 3.2% at both 5 and 10 years
[9e12,52e59] (Table 1). Factors correlated with LR included
larger tumor size (diameter,>2 cmor>3 cm), tumorwithout
encapsulation, poorly differentiated HCC, sub-capsular
location, ablative margin <1 cm, or the presence of a struc-
ture expected to provide heat-sink effects [9e12,52e55].
This increase in LR is presumably due to unexplored satellite
nodules, insufficient safety margin, or incomplete ablation
due to limitations of current imaging modalities in detection
of tumors [9e12,52e55]. Novel RF devices or refined algo-
rithms enhancing complete ablation may also minimize LR.
Table 1 Results of radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma.
Ref. No. of
cases
Maximum
tumor size
(cm)
Mean
follow-up
(mo)
Local recurrence (%):
1/2/3/5/10 y
New hepatic or
extrahepatic
recurrence (%):
1/3/5/10 y
Overall
recurrence (%):
1/3/5/10 y
Survival rate (%):
1/3/5/10 y
[9] 52 4 25 12/18/18/NA/NA 24/47/NA NA 90/74/NA/NA
[11] 118 3 37
(median)
1.3/1.7/1.7/1.7/NA NA 22/3/61/70
(4 y)
97/81/74(4 y)/NA
[56] 87 2 27.6
(median)
1.3/2.4/2.4/2.4/NA
(total cases)
NA NA 100/90.8/83.8/NA
215 2.1e5 27.6
(median)
NA NA 93/74.3/45.2/NA
[57] 206 5 24 14/ 49/ 81 18//55/83 97/67/41/NA
[54] 202 5 19 12/24/30
(30 mo)/NA/NA
13/30(30 mo)//NA 22//44
(30 mo)//NA
80/67/49(30 mo)/NA/NA
[59] 570 5 30 11.8a 52 NA
[8] 216 2 31 0.9a NA NA NA/76/55/NA
[58] 235 5 27 11.5a 42 NA NA/60/40/NA
[55] 1170 >5 38.2 1.4/3.2/3.2/3.2 25.6/74.8/78.1/80.8 NA 97/82.8/63.8/48.8/31
(for HCC 5 cm)
NA Z not available.
a Noncumulative rates only; value represents rate in the follow-up period.
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Because of underlying advanced liver disease in the
presence of HCC, additional new recurrence is very common
in patients with HCC. A recurrence rate of 81% was reported
at 4 years in small HCCs after RFA, a level comparable to that
seen after resection [54], but 5- and 10-year recurrence
rates of 74.8% and 80.8%, respectively, were reported by
Shiina et al in a 10-year follow-up [55]. Recurrence corre-
lated with platelet counts of 100  106/L, but only in the
study by Camma` et al [54]. Some investigators expressed
concern that RFA itself might induce the spread of tumors
[60]. Our study showed that the occurrence of a popping
sound (a possible indication of local pressure) during RFA did
not correlate with tumor progression [61]. Nevertheless, if
gas is observed spreading into adjacent vessels during RFA,
the electrode’s direction and/or position may have to be
changed in order to reduce the spread of tissue that may
have been incompletely coagulated at an earlier stage of
ablation [11]. Further study of the rate of rapid recurrence
of HCC and the associated factors or biomarkers might be
needed to elucidate the associated risk factors. For HCC in
high-risk locations, use of RFA at low RF power (<120 W) and
maximum power demonstrated that the former resulted in
fewer major complications [62].
Overall recurrence of HCC after RFA
The overall tumor recurrence rates of small HCCs after RFA
were 18e22% at 1 year, 30e48% at 2 years, 44e61% at 3
years, up to 71% at 4 years, and 83% at 5 years
[9e12,54,56,57]. Independent factors correlated with
higher overall recurrence of HCC included a low platelet
count (100  106/L), positive status for anti-hepatitis C
virus (anti-HCV) antibody, cirrhotic liver, increase inprothrombin time by >80%, multiple tumors, and higher
Edmondson’s grade (II or III) [11,54]. Overall HCC recur-
rence might be related to LR and tumor recurrence. To
increase complete necrosis, reduce LR, and prevent the
progression of underlying liver disease using antiviral ther-
apies for chronic hepatitis B or C which may also reduce
overall tumor recurrence [3,4].
Long-term survival of HCC patients after RFA
Data on long-term survival are very limited. A small number
of studies reported overall survival rates of 80e100% at 1
year, 63e98% at 2 years, 45e67% at 3 years, 74% at 4 years,
41e60% at 5 years, and 27e60% at 10 years
[9e12,54,56e59] (Table 1). Longer survival was commonly
observed in sub-groups with younger age, hepatitis C virus,
early Child-Pugh class, small tumor size, low serum or
lectin-reactive AFP level, low des-g-carboxyprothrombin
level, well-differentiated tumors, and solitary tumors
[9e12,54,56,57]. Recent studies have showed that RFA can
result in good 5-year survival rates (68% as reported by
Livraghi et al [8]; 76% as reported by N’Kontchou et al [58])
for very early stage operable HCC. Recent studies also
showed similar survival rates in very early stage or early
stage HCC when compared to resection [15,16], and com-
parable recurrence rates in very early stage HCC for the
two treatment modalities [15].
Comparison of RFA with resection
RFA has an efficacy equivalent to that of surgical resection
in small HCCs. Therefore, the 2012 European Association for
the Study of the Liver HCC guidelines (and some reports)
advocate that RFA can also be an option for patients with
very early stage (BCLC-0) HCC or BCLC-A-grade resectable
12 S.-M. LinHCC that is not suitable for resection. Some randomized or
cohort studies (with or without propensity score matching)
reported that RFA achieved a good 5-year survival rate for
very early stage operable HCC, and provided a survival rate
in very early stage or early stage HCC that was comparable
to that seen with resection [8,15,16,58,63,64] and compa-
rable recurrence in very early stage HCC [14,15] (Table 2).
Comparison of RFA with PEI and MWA
Among various local modalities, both PEI and RFA are the
most widely employed. Several randomized control trials,
cohort studies, and meta-analyses have shown that RFA is
superior to PEI for small HCCs, in terms of more predictable
necrosis in any size of HCC, higher complete ablation, lower
LR, and higher overall survival rate [8e11,17,18,29e32].
Conventional MWA provides only a 2 cm diameter thermal
ablation per electrode placed into the tumor; however, RFA
provides a 2e5 cm diameter thermal ablation per elec-
trode. Thus, RFA is more useful than MWA for the treatment
of small HCCs because RFA provides a lower LR rate, yields
a higher survival rate, and requires fewer treatment ses-
sions [65e67].
RF electrodes
Various RF electrodes (including deployed electrodes with
multiple tines, and internally cooled unipolar or bipolar
electrodes) are currently available. Some studies have
shown equivalent efficacy (regarding the complete necrosis
and local tumor progression) among the various RF elec-
trodes [44,65]. The characteristics of bipolar RF electrodes
preclude touching of the tumor when treating smaller tu-
mors; for HCC measuring <3 cm in diameter, the applicator
is outside the tumor but for HCC >3 cm in diameter the
applicator is inside the tumor, at a interprobe distanceTable 2 Studies comparing radiofrequency ablation and hepati
Ref. Study design Treatment
method
No. of patients Max siz
of tumo
[63] Cohort RFA C-P A: 43 NA
HR C-P A: 70 NA
RFA C-P B: 36 NA
HR C-P B: 9 NA
[14] RCT RFAa C-P A: 71 5/1
HR C-P A: 90 5/1
[15] Propensity RFA 66 2/1
HR 50 2/1
[16] Cohort RFA 91 2/1
HR 52
[16] RFA 254 3/3, 5/
HR 208
[64] RCT RFA 84 4/2
HR 84
C-P Z ChildePugh class; HCC Z hepatocellular carcinoma; HR Z
RCT Z randomized controlled trial; RFA Z radiofrequency ablation.
a Additional treatment with ethanol injection or chemoembolizatio
b 4-year survival rate.<3 cm [27]. The benefit of no-touch ablation includes
prevention of rupture of the tumor capsule, thereby pre-
sumably reducing the danger of tumors spreading before
ablation and reducing LR. However, no-touch ablation has
limitations, including difficulties in probe insertion for tu-
mors at high-risk locations or in narrow spaces. Addition-
ally, this technique may require free-hand insertion of
three to six probes [27].RFA for HCC in difficult-to-treat or high-risk
locations
RFA for HCC in difficult-to-treat or high-risk locations is
a challenge; spatial challenges can make it difficult to
achieve complete necrosis [18,46,68]. A “difficult-to-treat”
tumor is generally defined as a tumor located within 1 cm of
a vital structure, such as the GI tract, gallbladder,
diaphragm, visible intrahepatic bile duct, or vessel,
particularly vessels >3 mm in diameter [18,46,52,68].
Several strategies have been developed to counter these
problems. Combined use of ethanol injection and RFA
achieves a higher rate of complete necrosis than RFA
monotherapy in HCC in a high-risk location [46]. In addition,
we observed comparable clinical outcomes using RFA at low
RF power (120 W) and maximum RF power (>120 W), with
considerably fewer adverse effects encountered in the low-
power group, particularly in difficult-to-treat HCC [62].
Artificial ascites or artificial pleural effusion has also been
employed as an adjunct to percutaneous RFA for tumors in
problematic locations. The safety and efficacy of artificial
ascites or artificial pleural creation has been evaluated at
several sites [20,21,69,70]. Ultimately, open or laparo-
scopic RFA is also recommended as an alternative, but both
of these techniques are more invasive and require a tech-
nically demanding approach to electrode placement due to
limited access [71e73].c resection for hepatocellular carcinoma.
e (cm)/no.
r(s)
Overall survival rate (%) p
1-year 2-year 3-year 5-year
82 NA 43 NA 0.02
88 NA 71 NA
74 NA 25 NA NS
52 NA 19 NA
95.8 82.1 71.4 67.9b NS
93.3 82.3 73.4 64.0b
98.3 94.9 86.4 77.8 NS
100 95.9 91.1 84.6
96.7 NA 80.3 72 0.073
98 NA 98 91.5
1 91.6 NA 73.5 57.4 0.001
96.1 NA 87.8 71.2
93.1 83.1 67.2 NA 0.342
96 87.6 74.8 NA
hepatic resection; NA Z not available; NS Z not significant;
n.
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RF electrodes
Current RFA devices are more effective in HCC >3 cm in
diameter [18]. Recently, application of a switching RF
controller with simultaneous placement of unipolar or bi-
polar RF electrodes has been reported to create a larger
ablation in a shorter time [26e28]. Very limited but
promising preliminary results have been reported for
treatment of HCC with RFA administered via simultaneous
use of two or three RF electrodes and a switching RF gen-
erator [26e28]. In our center, we enrolled 70 patients with
at least one index HCC tumor 3.0 cm in diameter for
treatment (between 1 January 2009 and 31 December 2011)
using a switch-control RFA with 2e3 RF electrodes. Fifty-
three (75.7%) patients had a total of 58 index tumors of
medium size (3.0e4.9 cm in diameter), and the remaining
patients had a total of 17 large tumors (5.0e7.0 cm in
diameter). The mean diameters of the index tumors were
3.7  0.5 cm and 5.7  0.6 cm, respectively. The rates of
complete ablation after the first session were 79.3% (46/58)
and 82.4% (14/17), respectively. After an additional one or
two RFA sessions for each patient, the rate of primary
technique effectiveness was scored as 91.4% (medium-size
tumors) and 94.1% (large tumors). After a mean follow-up
of 21.0  10.2 months, 12 (18.8%) patients exhibited local
tumor progression and 10 (14.3%) patients had died. Esti-
mated cumulative overall survival rates and local tumor
progression rates were 93.9% and 84.6% (1 year), 81.3% and
10.7% (2 years), and 17.2% and 32.8% (3 years), respec-
tively. Comparing conventional RFA with single RF elec-
trode and sequential ablation, the rate of complete
ablation was 53e61% in medium-sized HCC and 20e45% in
large HCC. Seror et al used switching RFA and showed 81%
of complete ablation in HCC >5 cm [27], and Lee et al
showed 97% in HCC of 3.1e5 cm [28]. Therefore, RFA with
two or three electrodes and a switching RF generator ach-
ieved a high rate (>90%) of complete ablation for medium-
size and large HCC.
Moreover, RFA with multiple bipolar RF electrodes con-
nected via a switching RF generator could create a larger
coagulation necrosis by enabling placement of RFA elec-
trodes with interelectrode distances as great as 3 cm [27].
This method may reduce the risk of tumor spreading in
small HCC, since this technique permits the use of no-touch
RFA for tumors > 3 cm in diameter. From November 2010 to
April 2011, we enrolled six patients with solitary HCC >
2.5 cm in diameter. Three bipolar RFA electrodes were
placed just outside the margin of the tumor, and the pro-
cedure was conducted using a switching RF generator. The
results showed that the mean lengths of the three di-
mensions of the tumors were 1.6  0.3 cm, 1.6  0.4 cm,
and 2.1  0.4 cm before RFA and 3.8  0.4 cm,
3.2  0.6 cm, and 3.9  0.6 cm after RFA (all p < 0.05). The
total tumor volume before and after RFA were
3.0  1.4 cm3 and 24.5  6.0 cm3 (p < 0.001). Transient
postablative pain or fever (Grade 1e2) was reported. No LR
has been observed at >6 months of follow-up after RFA
(median follow-up, 10.2  2.5 months). These results sug-
gest that RFA using a switching RF generator, multiple bi-
polar RF electrodes, and a no-touch method mayeffectively ablate HCCs >3 cm in diameter with sufficient
safety margin and minimal risk of tumor spread. A larger
sample size and a longer observation period are required to
confirm potential clinical efficacy.Future perspectives
Recent advances in RFA include application of switching
RFA with several RF electrodes in the treatment of large
HCC with higher complete ablation rate and fewer ablation
sessions. However, further experimentation is required to
confirm the benefit(s) of switching RFA, particularly in
comparison to switching MWA, cryoablation, high-intensity
focused US, and electroporation. Additionally, the bene-
fit(s) of combination therapies using RFA with chemo-
embolization or other medications requires confirmation by
randomized or comparative studies. The assessment of the
efficacy of RFA may also be improved by using contrast
enhanced-US, with or without three-dimensional sonogra-
phy or real-time virtual sonography assistance.References
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